Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senate Drug Pricing Legislation Clears Committee With Generic Exclusivity “Parking” Provision Unchanged

Executive Summary

US Senate health committee advanced the Lower Health Care Costs Act with few pharma-related changes. Bill’s drug pricing provisions include the CREATES Act and a requirement that manufacturers report to HHS on price increases.

You may also be interested in...



Drug Development Questions Dominate Hahn's Confirmation, Despite Talk About E-Cigs

A plurality of the questions from the Senate HELP Committee at Stephen Hahn's confirmation hearing to head the US FDA focused on drug development issues, despite the time lawmakers spent discussing the agency's regulation of e-cigarettes.

Another US FDA Approval Record: ANDAs Set A New Annual High Mark In Only 10 Months

Office of Generic Drugs has granted full approvals to more than 800 ANDAs in fiscal year 2019, exceeding the previous mark reached in FY 2018.

US Drug Pricing Debate Enters Critical Phase: Two Visions For 2021

If the Senate's bipartisan price reform proposal is enacted into law this year, the drug pricing agenda for the next Administration will likely be set: implementing a host of changes to Medicare Part B, Part D and Medicaid. But if it fails, then more direct price negotiation measures will likely be the new starting point.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS125538

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel